Baricitinib for treating moderate to severe atopic dermatitis

  • Technology appraisal guidance
  • TA681
  • Published: 
Download guidance (PDF)

2 Information about baricitinib

Marketing authorisation indication

2.1 Baricitinib (Olumiant, Eli Lilly) is 'indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 A 28‑pack of 4‑mg tablets costs £805.56 (excluding VAT, BNF online, accessed December 2020). The company has a commercial arrangement. This makes baricitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.